Voyager Therapeutics Inc. (VYGR) NASDAQ
$7.30 (0.25) (-3.31%)
Market Cap: $409.97M
As of 04/19/24 02:56 PM EDT. Market open.
Voyager Therapeutics Inc. (VYGR)
NASDAQ
$7.30
(0.25) (-3.31%)
Market Cap: $409.97M
As of 04/19/24 02:56 PM EDT. Market open.
Add to Portfolio
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the ... read more
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
G. Andre Turenne
Full Time Employees
149
CEO Compensation (Base)
$240,000
CEO Compensation (Total)
$8.21M
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
G. Andre Turenne
Full Time Employees
149
CEO Compensation (Base)
$240,000
CEO Compensation (Total)
$8.21M
Address
75 Sidney St, Massachusetts, Cambridge, 02139-4134.
PRICE CHART FOR VOYAGER THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$7.50
Previous Close
$7.55
Days Range
$7.51 - $7.87
52 week range
$6.06 - $14.34
Volume
296,429
Avg. Volume (30 days)
669,289
Market Cap
$409.97M
Dividend Yield
-
P/E
3.10
Shares Outstanding
54,300,627
Open
$7.50
Previous Close
$7.55
Days Range
$7.51 - $7.87
52 week range
$6.06 - $14.34
Volume
296,429
Avg. Volume (30 days)
669,289
Market Cap
$409.97M
Dividend Yield
-
P/E
3.10
Shares Outstanding
54,300,627
FINANCIAL STATEMENTS FOR VOYAGER THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR VOYAGER THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Swartz Robin | Chief Operating Officer | Apr 02, 2024 | Sale | $9.88 | 1,357 | 13,407 | 117,004 | Apr 03, 2024, 04:13 PM |
| Sandrock Alfred | President and CEO | Apr 02, 2024 | Sale | $9.86 | 12,115 | 119,454 | 322,839 | Apr 03, 2024, 04:10 PM |
| Swartz Robin | Chief Operating Officer | Feb 21, 2024 | Sale | $7.45 | 3,966 | 29,547 | 118,361 | Feb 22, 2024, 04:36 PM |
| Sandrock Alfred | President and CEO | Feb 21, 2024 | Sale | $7.46 | 13,033 | 97,226 | 334,954 | Feb 22, 2024, 04:34 PM |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 21, 2024 | Sale | $7.46 | 3,764 | 28,079 | 175,669 | Feb 22, 2024, 04:32 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 21, 2024 | Sale | $7.47 | 3,365 | 25,137 | 87,627 | Feb 22, 2024, 04:30 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 20, 2024 | Sale | $7.68 | 602 | 4,623 | 90,992 | Feb 22, 2024, 04:30 PM |
| Swartz Robin | Chief Operating Officer | Jan 17, 2024 | Sale | $7.15 | 2,543 | 18,182 | 72,327 | Jan 19, 2024, 04:34 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 17, 2024 | Sale | $7.18 | 1,266 | 9,090 | 53,094 | Jan 19, 2024, 04:32 PM |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Oct 03, 2023 | Sale | $6.99 | 13,567 | 94,833 | 149,433 | Oct 05, 2023, 04:41 PM |
| Carter Todd Alfred | Chief Scientific Officer | Sep 15, 2023 | Option Exercise | $2.85 | 5,000 | 14,250 | 64,860 | Sep 18, 2023, 04:44 PM |
| Carter Todd Alfred | Chief Scientific Officer | Sep 15, 2023 | Sale | $8.16 | 10,500 | 85,680 | 54,360 | Sep 18, 2023, 04:44 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jul 06, 2023 | Sale | $10.80 | 5,500 | 59,400 | 59,860 | Jul 10, 2023, 04:42 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jun 30, 2023 | Option Exercise | $2.85 | 5,000 | 14,250 | 70,360 | Jul 05, 2023, 04:32 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jun 30, 2023 | Sale | $11.41 | 5,000 | 57,050 | 65,360 | Jul 05, 2023, 04:32 PM |
| Sandrock Alfred | President and CEO | Apr 03, 2023 | Sale | $7.83 | 7,437 | 58,232 | 214,618 | Apr 05, 2023, 05:04 PM |
| Swartz Robin | Chief Operating Officer | Apr 03, 2023 | Sale | $7.83 | 1,259 | 9,858 | 71,617 | Apr 05, 2023, 05:02 PM |
| Carter Todd Alfred | Chief Scientific Officer | Mar 20, 2023 | Sale | $7.76 | 2,193 | 17,018 | 65,360 | Mar 22, 2023, 04:49 PM |
| Swartz Robin | Chief Operating Officer | Mar 20, 2023 | Sale | $7.76 | 3,654 | 28,355 | 72,876 | Mar 22, 2023, 04:48 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Mar 20, 2023 | Sale | $7.76 | 4,410 | 34,222 | 102,200 | Mar 22, 2023, 04:47 PM |
| Swartz Robin | Chief Operating Officer | Mar 15, 2023 | Sale | $8.20 | 15,373 | 126,059 | 76,530 | Mar 17, 2023, 04:37 PM |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | Feb 23, 2023 | Buy | $8.88 | 4,395,588 | 39,032,822 | 8,575,316 | Feb 24, 2023, 06:15 AM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 17, 2023 | Sale | $7.45 | 3,297 | 24,563 | 106,610 | Feb 22, 2023, 08:58 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 17, 2023 | Sale | $7.45 | 738 | 5,498 | 67,553 | Feb 22, 2023, 08:57 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 13, 2023 | Sale | $7.67 | 797 | 6,113 | 34,291 | Feb 15, 2023, 04:53 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 13, 2023 | Sale | $7.67 | 2,868 | 21,998 | 109,907 | Feb 15, 2023, 04:52 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Feb 01, 2023 | Sale | $9.32 | 128,642 | 1,198,943 | 4,685,291 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 31, 2023 | Sale | $9.25 | 185,000 | 1,711,250 | 4,813,933 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 30, 2023 | Sale | $9.03 | 75,000 | 677,250 | 4,998,933 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 27, 2023 | Sale | $9.02 | 50,000 | 451,000 | 5,073,933 | Jan 31, 2023, 04:30 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 25, 2023 | Sale | $9.22 | 50,000 | 461,000 | 5,123,933 | Jan 26, 2023, 05:23 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 24, 2023 | Sale | $9.27 | 100,000 | 927,000 | 5,173,933 | Jan 26, 2023, 05:23 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 23, 2023 | Sale | $9.06 | 55,000 | 498,300 | 5,273,933 | Jan 24, 2023, 06:20 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 20, 2023 | Sale | $9.15 | 100,000 | 915,000 | 5,328,933 | Jan 24, 2023, 06:20 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Jan 17, 2023 | Sale | $9.85 | 2,188 | 21,549 | 113,567 | Jan 19, 2023, 04:57 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 17, 2023 | Sale | $9.85 | 1,106 | 10,892 | 35,488 | Jan 19, 2023, 04:55 PM |
| Swartz Robin | Chief Operating Officer | Jan 17, 2023 | Sale | $9.85 | 2,188 | 21,549 | 52,695 | Jan 19, 2023, 04:53 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 09, 2023 | Sale | $7.67 | 456,000 | 3,498,295 | 4,297,907 | Jan 11, 2023, 06:26 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 11, 2023 | Sale | $8.50 | 110,000 | 934,615 | 3,851,507 | Jan 11, 2023, 06:26 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 10, 2023 | Sale | $8.05 | 336,400 | 2,709,433 | 3,961,507 | Jan 11, 2023, 06:26 PM |
| Carter Todd Alfred | Chief Scientific Officer | Dec 31, 2022 | Option Exercise | $5.17 | 388 | 2,006 | 36,582 | Jan 10, 2023, 04:07 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 06, 2023 | Sale | $6.41 | 388 | 2,487 | 36,194 | Jan 10, 2023, 04:07 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 25, 2022 | Sale | $6.22 | 200,000 | 1,244,000 | 5,428,933 | Aug 26, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 24, 2022 | Sale | $6.09 | 149,972 | 913,330 | 5,628,933 | Aug 26, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 16, 2022 | Sale | $6.04 | 128,456 | 775,874 | 5,778,905 | Aug 18, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 12, 2022 | Sale | $6.12 | 348,007 | 2,129,803 | 6,043,169 | Aug 16, 2022, 04:22 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 15, 2022 | Sale | $6.04 | 135,808 | 820,280 | 5,907,361 | Aug 16, 2022, 04:22 PM |
| PIERCE GLENN | Director | Jul 14, 2022 | Sale | $6.70 | 9,512 | 63,730 | 16,788 | Jul 18, 2022, 05:34 PM |
| Higgins Michael J | Director | Jul 14, 2022 | Sale | $6.70 | 13,891 | 93,070 | 31,314 | Jul 18, 2022, 05:32 PM |
| EcoR1 Capital, LLC | 10% Owner | Jun 23, 2022 | Buy | $5.66 | 376,000 | 2,126,543 | 4,753,907 | Jun 23, 2022, 05:21 PM |
| EcoR1 Capital, LLC | 10% Owner | Jun 21, 2022 | Buy | $5.28 | 101,400 | 535,504 | 4,377,907 | Jun 23, 2022, 05:21 PM |
| Swartz Robin | Chief Operating Officer | Apr 04, 2022 | Sale | $8.25 | 1,527 | 12,598 | 52,060 | Apr 06, 2022, 04:34 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 04, 2022 | Sale | $8.25 | 2,786 | 22,985 | 114,963 | Apr 06, 2022, 04:34 PM |
| Swartz Robin | Chief Operating Officer | Mar 21, 2022 | Sale | $8.29 | 4,413 | 36,604 | 53,638 | Mar 23, 2022, 06:40 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Mar 21, 2022 | Sale | $8.29 | 4,955 | 41,100 | 117,807 | Mar 23, 2022, 06:39 PM |
| Burek Julie | VP, Finance | Mar 21, 2022 | Sale | $8.29 | 2,649 | 21,972 | 52,489 | Mar 23, 2022, 06:36 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 17, 2022 | Sale | $3.55 | 4,100 | 14,555 | 122,704 | Feb 22, 2022, 04:37 PM |
| Burek Julie | VP, Finance | Feb 17, 2022 | Sale | $3.55 | 789 | 2,801 | 55,107 | Feb 22, 2022, 04:35 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 11, 2022 | Sale | $3.36 | 3,252 | 10,927 | 126,804 | Feb 15, 2022, 04:42 PM |
| Burek Julie | VP, Finance | Feb 11, 2022 | Sale | $3.36 | 361 | 1,213 | 55,896 | Feb 15, 2022, 04:40 PM |
| Burek Julie | VP, Finance | Dec 31, 2021 | Option Exercise | $2.30 | 3,063 | 7,045 | 49,585 | Jan 14, 2022, 06:14 PM |
| Burek Julie | VP, Finance | Jan 12, 2022 | Sale | $3.06 | 265 | 811 | 46,257 | Jan 14, 2022, 06:14 PM |
| Burek Julie | VP, Finance | Jan 03, 2022 | Sale | $2.83 | 3,063 | 8,668 | 46,522 | Jan 14, 2022, 06:14 PM |
| Khwaja Omar | See remarks | May 21, 2021 | Sale | $4.03 | 3,516 | 14,169 | 120,509 | May 25, 2021, 04:31 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 05, 2021 | Sale | $4.95 | 3,292 | 16,295 | 110,056 | Apr 07, 2021, 05:44 PM |
| Dorval Allison | Chief Financial Officer | Feb 11, 2021 | Sale | $7.55 | 3,186 | 24,054 | 45,894 | Feb 16, 2021, 04:10 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 11, 2021 | Sale | $7.55 | 3,186 | 24,054 | 49,348 | Feb 16, 2021, 04:08 PM |
| Khwaja Omar | See remarks | Feb 11, 2021 | Sale | $7.55 | 3,475 | 26,236 | 53,025 | Feb 16, 2021, 04:06 PM |
| Turenne Andre | President & CEO | Feb 11, 2021 | Sale | $7.55 | 7,977 | 60,226 | 148,375 | Feb 16, 2021, 12:00 AM |
| Turenne Andre | President & CEO | Jan 12, 2021 | Sale | $8.62 | 10,443 | 90,019 | 156,352 | Jan 14, 2021, 05:59 PM |
| Dorval Allison | Chief Financial Officer | Jan 12, 2021 | Sale | $8.62 | 2,942 | 25,360 | 49,080 | Jan 14, 2021, 05:57 PM |
| Khwaja Omar | See remarks | May 21, 2020 | Sale | $12.96 | 3,500 | 45,360 | 56,500 | May 22, 2020, 06:15 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 03, 2020 | Sale | $8.51 | 3,091 | 26,304 | 52,534 | Apr 07, 2020, 05:24 PM |
| Dorval Allison | Chief Financial Officer | Jan 21, 2020 | Sale | $13.36 | 3,128 | 41,790 | 24,522 | Jan 29, 2020, 05:27 PM |
| Ottmer Matthew P. | Chief Operating Officer | Jan 21, 2020 | Sale | $13.36 | 3,724 | 49,753 | 26,276 | Jan 29, 2020, 05:26 PM |
| Turenne Andre | President & CEO | Jan 21, 2020 | Sale | $13.36 | 10,705 | 143,019 | 85,545 | Jan 29, 2020, 05:26 PM |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | Mar 12, 2019 | Buy | $11.96 | 4,179,728 | 49,999,995 | 4,179,728 | Mar 14, 2019, 04:34 PM |
| PIERCE GLENN | Director | Sep 12, 2018 | Buy | $18.44 | 5,000 | 92,200 | 5,000 | Sep 12, 2018, 12:00 AM |
| GERAGHTY JAMES A | Director | Sep 10, 2018 | Buy | $19.39 | 3,000 | 58,170 | 76,588 | Sep 12, 2018, 12:00 AM |
| GERAGHTY JAMES A | Director | Aug 17, 2018 | Buy | $18.31 | 3,000 | 54,930 | 73,588 | Aug 21, 2018, 04:05 PM |
| Ravina Bernard | Chief Medical Officer | Apr 10, 2018 | Sale | $18.38 | 2,451 | 45,049 | 0 | Apr 12, 2018, 04:01 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 22, 2018 | Option Exercise | $11.97 | 19,900 | 238,203 | 19,900 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 23, 2018 | Option Exercise | $11.97 | 11,200 | 134,064 | 11,200 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 23, 2018 | Sale | $20.52 | 11,200 | 229,824 | 0 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 22, 2018 | Sale | $21.07 | 19,900 | 419,293 | 0 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 19, 2018 | Option Exercise | $11.97 | 1,900 | 22,743 | 1,900 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 16, 2018 | Option Exercise | $11.97 | 15,416 | 184,530 | 15,416 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 19, 2018 | Sale | $21.76 | 1,900 | 41,344 | 0 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 16, 2018 | Sale | $22.15 | 15,416 | 341,464 | 0 | Mar 20, 2018, 05:43 PM |
| Ravina Bernard | Chief Medical Officer | Mar 12, 2018 | Sale | $25.16 | 2,451 | 61,667 | 2,451 | Mar 14, 2018, 04:07 PM |
| Sah Dinah Ph.D. | Chief Scientific Officer | Feb 27, 2018 | Option Exercise | $9.98 | 15,623 | 155,845 | 154,311 | Mar 01, 2018, 06:00 PM |
| Sah Dinah Ph.D. | Chief Scientific Officer | Feb 27, 2018 | Sale | $30.00 | 15,623 | 468,690 | 138,688 | Mar 01, 2018, 06:00 PM |
| Ravina Bernard | Chief Medical Officer | Feb 12, 2018 | Sale | $18.24 | 2,451 | 44,706 | 4,902 | Feb 13, 2018, 04:10 PM |
| Ravina Bernard | Chief Medical Officer | Jan 10, 2018 | Sale | $16.40 | 3,630 | 59,532 | 7,353 | Jan 12, 2018, 08:57 AM |
| Ravina Bernard | Chief Medical Officer | Dec 11, 2017 | Sale | $13.63 | 5,490 | 74,829 | 10,983 | Dec 13, 2017, 04:02 PM |
| Ravina Bernard | Chief Medical Officer | Nov 10, 2017 | Sale | $13.26 | 5,490 | 72,797 | 16,473 | Nov 13, 2017, 04:15 PM |
| Ravina Bernard | Chief Medical Officer | Oct 10, 2017 | Sale | $20.33 | 10,980 | 223,223 | 21,963 | Oct 12, 2017, 07:28 PM |
| Ravina Bernard | Chief Medical Officer | Sep 11, 2017 | Sale | $14.30 | 10,980 | 157,014 | 32,943 | Sep 13, 2017, 05:23 PM |
| Ravina Bernard | Chief Medical Officer | Jul 20, 2017 | Sale | $10.00 | 5,490 | 54,900 | 49,413 | Sep 13, 2017, 05:23 PM |
| Ravina Bernard | Chief Medical Officer | Sep 05, 2017 | Sale | $10.00 | 5,490 | 54,900 | 17,157 | Sep 06, 2017, 04:38 PM |
| PAUL STEVEN M | President and CEO | Jan 14, 2016 | Buy | $14.07 | 10,000 | 140,690 | 872,351 | Jan 15, 2016, 05:01 PM |
| Sanofi | Former 10% owner | Nov 16, 2015 | Buy | $14.00 | 125,000 | 1,750,000 | 2,477,941 | Nov 18, 2015, 02:26 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Swartz Robin | Chief Operating Officer | 04/02/2024 | 13,407 |
| Sandrock Alfred | President and CEO | 04/02/2024 | 119,454 |
| Swartz Robin | Chief Operating Officer | 02/21/2024 | 29,547 |
| Sandrock Alfred | President and CEO | 02/21/2024 | 97,226 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 02/21/2024 | 28,079 |
| Carter Todd Alfred | Chief Scientific Officer | 02/21/2024 | 25,137 |
| Carter Todd Alfred | Chief Scientific Officer | 02/20/2024 | 4,623 |
| Swartz Robin | Chief Operating Officer | 01/17/2024 | 18,182 |
| Carter Todd Alfred | Chief Scientific Officer | 01/17/2024 | 9,090 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 10/03/2023 | 94,833 |
| Carter Todd Alfred | Chief Scientific Officer | 09/15/2023 | 14,250 |
| Carter Todd Alfred | Chief Scientific Officer | 09/15/2023 | 85,680 |
| Carter Todd Alfred | Chief Scientific Officer | 07/06/2023 | 59,400 |
| Carter Todd Alfred | Chief Scientific Officer | 06/30/2023 | 14,250 |
| Carter Todd Alfred | Chief Scientific Officer | 06/30/2023 | 57,050 |
| Sandrock Alfred | President and CEO | 04/03/2023 | 58,232 |
| Swartz Robin | Chief Operating Officer | 04/03/2023 | 9,858 |
| Carter Todd Alfred | Chief Scientific Officer | 03/20/2023 | 17,018 |
| Swartz Robin | Chief Operating Officer | 03/20/2023 | 28,355 |
| Hesslein Robert W. | Senior VP & General Counsel | 03/20/2023 | 34,222 |
| Swartz Robin | Chief Operating Officer | 03/15/2023 | 126,059 |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | 02/23/2023 | 39,032,822 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/17/2023 | 24,563 |
| Carter Todd Alfred | Chief Scientific Officer | 02/17/2023 | 5,498 |
| Carter Todd Alfred | Chief Scientific Officer | 02/13/2023 | 6,113 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/13/2023 | 21,998 |
| Third Rock Ventures III, L.P. | 10% Owner | 02/01/2023 | 1,198,943 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/31/2023 | 1,711,250 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/30/2023 | 677,250 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/27/2023 | 451,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/25/2023 | 461,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/24/2023 | 927,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/23/2023 | 498,300 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/20/2023 | 915,000 |
| Hesslein Robert W. | Senior VP & General Counsel | 01/17/2023 | 21,549 |
| Carter Todd Alfred | Chief Scientific Officer | 01/17/2023 | 10,892 |
| Swartz Robin | Chief Operating Officer | 01/17/2023 | 21,549 |
| EcoR1 Capital, LLC | 10% Owner | 01/09/2023 | 3,498,295 |
| EcoR1 Capital, LLC | 10% Owner | 01/11/2023 | 934,615 |
| EcoR1 Capital, LLC | 10% Owner | 01/10/2023 | 2,709,433 |
| Carter Todd Alfred | Chief Scientific Officer | 12/31/2022 | 2,006 |
| Carter Todd Alfred | Chief Scientific Officer | 01/06/2023 | 2,487 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/25/2022 | 1,244,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/24/2022 | 913,330 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/16/2022 | 775,874 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/12/2022 | 2,129,803 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/15/2022 | 820,280 |
| PIERCE GLENN | Director | 07/14/2022 | 63,730 |
| Higgins Michael J | Director | 07/14/2022 | 93,070 |
| EcoR1 Capital, LLC | 10% Owner | 06/23/2022 | 2,126,543 |
| EcoR1 Capital, LLC | 10% Owner | 06/21/2022 | 535,504 |
| Swartz Robin | Chief Operating Officer | 04/04/2022 | 12,598 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/04/2022 | 22,985 |
| Swartz Robin | Chief Operating Officer | 03/21/2022 | 36,604 |
| Hesslein Robert W. | Senior VP & General Counsel | 03/21/2022 | 41,100 |
| Burek Julie | VP, Finance | 03/21/2022 | 21,972 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/17/2022 | 14,555 |
| Burek Julie | VP, Finance | 02/17/2022 | 2,801 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/11/2022 | 10,927 |
| Burek Julie | VP, Finance | 02/11/2022 | 1,213 |
| Burek Julie | VP, Finance | 12/31/2021 | 7,045 |
| Burek Julie | VP, Finance | 01/12/2022 | 811 |
| Burek Julie | VP, Finance | 01/03/2022 | 8,668 |
| Khwaja Omar | See remarks | 05/21/2021 | 14,169 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/05/2021 | 16,295 |
| Dorval Allison | Chief Financial Officer | 02/11/2021 | 24,054 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/11/2021 | 24,054 |
| Khwaja Omar | See remarks | 02/11/2021 | 26,236 |
| Turenne Andre | President & CEO | 02/11/2021 | 60,226 |
| Turenne Andre | President & CEO | 01/12/2021 | 90,019 |
| Dorval Allison | Chief Financial Officer | 01/12/2021 | 25,360 |
| Khwaja Omar | See remarks | 05/21/2020 | 45,360 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/03/2020 | 26,304 |
| Dorval Allison | Chief Financial Officer | 01/21/2020 | 41,790 |
| Ottmer Matthew P. | Chief Operating Officer | 01/21/2020 | 49,753 |
| Turenne Andre | President & CEO | 01/21/2020 | 143,019 |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | 03/12/2019 | 49,999,995 |
| PIERCE GLENN | Director | 09/12/2018 | 92,200 |
| GERAGHTY JAMES A | Director | 09/10/2018 | 58,170 |
| GERAGHTY JAMES A | Director | 08/17/2018 | 54,930 |
| Ravina Bernard | Chief Medical Officer | 04/10/2018 | 45,049 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/22/2018 | 238,203 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/23/2018 | 134,064 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/23/2018 | 229,824 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/22/2018 | 419,293 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/19/2018 | 22,743 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/16/2018 | 184,530 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/19/2018 | 41,344 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/16/2018 | 341,464 |
| Ravina Bernard | Chief Medical Officer | 03/12/2018 | 61,667 |
| Sah Dinah Ph.D. | Chief Scientific Officer | 02/27/2018 | 155,845 |
| Sah Dinah Ph.D. | Chief Scientific Officer | 02/27/2018 | 468,690 |
| Ravina Bernard | Chief Medical Officer | 02/12/2018 | 44,706 |
| Ravina Bernard | Chief Medical Officer | 01/10/2018 | 59,532 |
| Ravina Bernard | Chief Medical Officer | 12/11/2017 | 74,829 |
| Ravina Bernard | Chief Medical Officer | 11/10/2017 | 72,797 |
| Ravina Bernard | Chief Medical Officer | 10/10/2017 | 223,223 |
| Ravina Bernard | Chief Medical Officer | 09/11/2017 | 157,014 |
| Ravina Bernard | Chief Medical Officer | 07/20/2017 | 54,900 |
| Ravina Bernard | Chief Medical Officer | 09/05/2017 | 54,900 |
| PAUL STEVEN M | President and CEO | 01/14/2016 | 140,690 |
| Sanofi | Former 10% owner | 11/16/2015 | 1,750,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN VOYAGER THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 2,632,679 | 0.00057% | 6.79% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 1,292,000 | 0.05% | No change | Event Driven, Value |
| GEODE CAPITAL MANAGEMENT, LLC | 678,878 | 0.0006% | 4.94% | Other |
| AQR CAPITAL MANAGEMENT LLC | 639,287 | 0.01% | 221.54% | Other |
| D. E. SHAW & CO., INC. | 406,044 | 0.00299% | -35.15% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 183,100 | 0.00239% | -54.63% | Other |
| BLACKSTONE INC. | 50,848 | 0.00193% | No change | Other |
| ALPS ADVISORS INC | 35,436 | 0.00235% | -6.5% | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 15,487 | 0.00241% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR VOYAGER THERAPEUTICS INC
STOCK BUYBACKS FOR VOYAGER THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
15.00%
1Q
06/30/2023
15.91%
2Q
03/31/2023
19.65%
3Q
12/31/2022
30.86%
4Q
09/30/2022
27.48%
5Q
06/30/2022
31.72%
6Q
03/31/2022
32.58%
7Q
12/31/2021
33.43%
8Q
09/30/2021
33.52%
9Q
06/30/2021
34.23%
10Q
03/31/2021
34.52%
11Q
12/31/2020
36.73%
12Q
09/30/2020
33.91%
13Q
06/30/2020
36.23%
14Q
03/31/2020
36.47%
15Q
12/31/2019
36.90%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR VOYAGER THERAPEUTICS INC
LOADING...